Wedbush Reaffirms “Buy” Rating for Millendo Therapeutics (NASDAQ:MLND)

Wedbush reiterated their buy rating on shares of Millendo Therapeutics (NASDAQ:MLND) in a report issued on Thursday, AnalystRatings.com reports. Wedbush currently has a $24.00 price objective on the stock. Wedbush also issued estimates for Millendo Therapeutics’ Q4 2019 earnings at ($1.01) EPS, FY2019 earnings at ($3.45) EPS and FY2020 earnings at ($3.52) EPS.

Several other analysts also recently issued reports on the stock. Oppenheimer reduced their price target on shares of Millendo Therapeutics from $26.00 to $25.00 and set an outperform rating for the company in a research report on Tuesday, August 13th. ValuEngine raised shares of Millendo Therapeutics from a hold rating to a buy rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Millendo Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 16th. Citigroup initiated coverage on shares of Millendo Therapeutics in a research report on Monday, July 15th. They issued an outperform rating and a $26.00 price target for the company. Finally, CIBC initiated coverage on shares of Millendo Therapeutics in a research report on Tuesday, July 16th. They issued an outperform rating and a $26.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Millendo Therapeutics has a consensus rating of Buy and an average price target of $22.97.

NASDAQ MLND opened at $6.98 on Thursday. The company has a fifty day simple moving average of $10.18 and a 200 day simple moving average of $13.06. Millendo Therapeutics has a 12-month low of $6.63 and a 12-month high of $17.34. The company has a current ratio of 5.90, a quick ratio of 7.83 and a debt-to-equity ratio of 0.04. The company has a market cap of $91.47 million, a P/E ratio of -0.40 and a beta of 2.64.

Millendo Therapeutics (NASDAQ:MLND) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.07. Sell-side analysts predict that Millendo Therapeutics will post -3.22 EPS for the current year.

Large investors have recently modified their holdings of the business. Strs Ohio bought a new position in Millendo Therapeutics during the 2nd quarter valued at $28,000. JPMorgan Chase & Co. lifted its stake in Millendo Therapeutics by 285.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,580 shares of the company’s stock valued at $29,000 after acquiring an additional 1,911 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Millendo Therapeutics by 270.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,593 shares of the company’s stock valued at $30,000 after acquiring an additional 1,893 shares in the last quarter. Geode Capital Management LLC bought a new position in Millendo Therapeutics during the 4th quarter valued at $113,000. Finally, Wells Fargo & Company MN lifted its stake in Millendo Therapeutics by 1,830.5% during the 2nd quarter. Wells Fargo & Company MN now owns 14,479 shares of the company’s stock valued at $168,000 after acquiring an additional 13,729 shares in the last quarter. Institutional investors and hedge funds own 44.03% of the company’s stock.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Recommended Story: What does a hold rating mean?

Analyst Recommendations for Millendo Therapeutics (NASDAQ:MLND)

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.